

Annual accounts 2019 - AGM approval

Firmanavn

DrugStars ApS

Firmaadresse

Emdrupvej 28A

CVR-nr

36893974

„Sender”



Financial Statements 2019

Firmanavn

DrugStars ApS

Firmaadresse

Emdrupvej 28A

CVR-nr

36893974

„Sender”

Drugstars ApS

Emdrupvej 28 A, 4., DK-2100 Copenhagen Ø

CVR no. 36 89 39 74

Annual report 2019

Approved at the Company's annual general meeting on

Chairman:

.....





Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements 1 January - 31 December	7
Income statement	7
Balance sheet	8
Statement of changes in equity	10
Notes to the financial statements	11



Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drugstars ApS for the financial year 1 January - 31 December 2019.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2019 and of the results of the Company's operations for the financial year 1 January - 31 December 2019.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 31 March 2020
Executive Board:

.....
Claus Møldrup
CEO

Board of Directors:

.....
Henrik Holmark
Chairman

.....
Ulli Jendrik Koop

.....
Ekaterina Gianelli

.....
Eric Thomas Lagier

.....
Anders Kjær

.....
Christian Hjortgaard

.....
Jesper Kilbæk

Independent auditor's report

To the shareholders of Drugstars ApS

Opinion

We have audited the financial statements of Drugstars ApS for the financial year 1 January - 31 December 2019, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2019 and of the results of the Company's operations for the financial year 1 January - 31 December 2019 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

Material uncertainty related to going concern

We draw attention to the fact that the Company's ability to continue as a going concern is associated with significant uncertainty. We refer to note 2 in the financial statements, which describes the uncertainty in respect of going concern and assumptions applied by Management. We have not modified our opinion in respect of this matter.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Independent auditor's report

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 31 March 2020
ERNST & YOUNG
Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Rasmus Bloch Jespersen
State Authorised Public Accountant
mne35503

Management's review

Company details

Name	Drugstars ApS
Address, Postal code, City	Emdrupvej 28 A, 4., DK-2100 Copenhagen Ø
CVR no.	36 89 39 74
Established	13 May 2015
Registered office	Copenhagen
Financial year	1 January - 31 December
Website	www.drugstars.dk
Board of Directors	Henrik Holmark, Chairman Ulli Jendrik Koop Ekaterina Gianelli Eric Thomas Lagier Anders Kjær Christian Hjortgaard Jesper Kilbæk
Executive Board	Claus Møldrup, CEO
Auditors	Ernst & Young Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

Management's review

Business review

The Company's principal activity is software development.

Unusual matters having affected the financial statements

Going concern

On 31 December 2019, Drugstars had a cash position of approximately DKK 7.5 million. In Management's assessment, this provides the Company with sufficient funds to meet its operational liquidity requirements through the end of November 2020.

Management is working towards a financing round with current and potential new investors. Management believes that the financing round will be completed in due time before December 2020 and secure funding to meet the Company's operational liquidity requirements at least through 2020. On this basis, Management presents the financial statements for 2019 on a going concern assumption.

Due to the uncertainty associated with the completion of the financing round, significant uncertainties regarding going concern exist, and therefore the Company may be unable to realise its assets and discharge its liabilities in the normal course of business.

Financial review

The income statement for 2019 shows a loss of DKK 8,330,135 against a loss of DKK 3,999,207 last year, and the balance sheet at 31 December 2019 shows equity of DKK 6,591,437.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Financial statements 1 January - 31 December

Income statement

Note	DKK	2019	2018
	Revenue	1,061,292	1,131,729
	Cost of sales	-1,412,136	-492,795
	Other operating income	0	245,750
	Other external expenses	-4,045,711	-3,123,585
	Gross profit	-4,396,555	-2,238,901
3	Staff costs	-4,670,223	-2,442,600
	Depreciation of property, plant and equipment	-19,646	0
	Profit/loss before net financials	-9,086,424	-4,681,501
	Financial income	1,277	4,346
	Financial expenses	-77,895	-1,158
	Profit/loss before tax	-9,163,042	-4,678,313
	Tax for the year	832,907	679,106
	Profit/loss for the year	-8,330,135	-3,999,207
	Recommended appropriation of profit/loss		
	Retained earnings/accumulated loss	-8,330,135	-3,999,207
		-8,330,135	-3,999,207

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	<u>2019</u>	<u>2018</u>
	ASSETS		
	Fixed assets		
4	Property, plant and equipment		
	Fixtures and fittings, other plant and equipment	100,620	0
		<u>100,620</u>	<u>0</u>
	Total fixed assets	<u>100,620</u>	<u>0</u>
	Non-fixed assets		
	Receivables		
	Trade receivables	498,750	304,861
	Corporation tax receivable	832,907	679,106
	Other receivables	60,463	107,576
		<u>1,392,120</u>	<u>1,091,543</u>
	Cash	7,486,890	254,474
	Total non-fixed assets	<u>8,879,010</u>	<u>1,346,017</u>
	TOTAL ASSETS	<u>8,979,630</u>	<u>1,346,017</u>

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	2019	2018
	EQUITY AND LIABILITIES		
	Equity		
5	Share capital	196,737	140,793
	Retained earnings	6,394,700	233,230
	Total equity	<u>6,591,437</u>	<u>374,023</u>
	Liabilities other than provisions		
	Current liabilities other than provisions		
	Bank debt	0	274
	Trade payables	51,418	758,424
	Other payables	1,321,951	213,296
	Deferred income	1,014,824	0
		<u>2,388,193</u>	<u>971,994</u>
	Total liabilities other than provisions	<u>2,388,193</u>	<u>971,994</u>
	TOTAL EQUITY AND LIABILITIES	<u>8,979,630</u>	<u>1,346,017</u>

- 1 Accounting policies
- 2 Going concern uncertainties
- 6 Contractual obligations and contingencies, etc.
- 7 Contingent assets

Financial statements 1 January - 31 December

Statement of changes in equity

DKK	Share capital	Retained earnings	Total
Equity at 1 January 2018	133,300	2,741,330	2,874,630
Capital increase	7,493	1,491,107	1,498,600
Transfer through appropriation of loss	0	-3,999,207	-3,999,207
	140,793	233,230	374,023
Equity at 1 January 2019	140,793	233,230	374,023
Capital increase	55,944	14,865,853	14,921,797
Expenses, capital increase	0	-374,248	-374,248
Transfer through appropriation of loss	0	-8,330,135	-8,330,135
	196,737	6,394,700	6,591,437
Equity at 31 December 2019	196,737	6,394,700	6,591,437

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Drugstars ApS for 2019 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Revenue

The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition.

Income from the rendering of services is recognised as revenue as the services are rendered. Accordingly, revenue corresponds to the market value of the services rendered during the year.

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Depreciation

The item comprises depreciation of property, plant and equipment.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Fixtures and fittings, other plant and equipment	3-5 years
--	-----------

Depreciation is based on the residual value of the asset and is reduced by impairment losses, if any. The depreciation period and the residual value are determined at the acquisition date and are reassessed annually. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised.

In the case of changes in the depreciation period or the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

Financial income and expenses

Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Gains or losses are calculated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses from the disposal of property, plant and equipment are recognised in the income statement as other operating income or other operating expenses.

Impairment of fixed assets

The carrying amount of intangible assets, property, plant and equipment and investments in subsidiaries and associates is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists. Impairment losses on goodwill are not reversed.

Receivables

Receivables are measured at amortised cost.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

An impairment loss is recognised if there is objective evidence that a receivable is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Cash

Cash comprise cash in banks.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Liabilities

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Deferred income

Deferred income recognised as a liability comprises payments received concerning income in subsequent financial reporting years.

2 Going concern uncertainties

On 31 December 2019, Drugstars had a cash position of approximately DKK 7.5 million. In Management's assessment, this provides the Company with sufficient funds to meet its operational liquidity requirements through the end of November 2020.

Management is working towards a financing round with current and potential new investors. Management believes that the financing round will be completed in due time before December 2020 and secure funding to meet the Company's operational liquidity requirements at least through 2020. On this basis, Management presents the financial statements for 2019 on a going concern assumption.

Due to the uncertainty associated with the completion of the financing round, significant uncertainties regarding going concern exist, and therefore the Company may be unable to realise its assets and discharge its liabilities in the normal course of business.

DKK	2019	2018
3 Staff costs and incentive programmes		
Wages/salaries	4,512,863	2,323,537
Pensions	80,393	81,859
Other social security costs	56,221	30,091
Other staff costs	20,746	7,113
	<u>4,670,223</u>	<u>2,442,600</u>
	2019	2018
Average number of full-time employees	<u>10</u>	<u>6</u>

Incentive programmes

The Company has introduced a share-based incentive plan aimed at members of the Executive Board/Board of Directors. Share-based awards are granted subject to the fulfilment of certain performance targets, both in the short and in the long run.

4 Property, plant and equipment

DKK	Fixtures and fittings, other plant and equipment
Additions	<u>120,266</u>
Cost at 31 December 2019	<u>120,266</u>
Depreciation	<u>19,646</u>
Impairment losses and depreciation at 31 December 2019	<u>19,646</u>
Carrying amount at 31 December 2019	<u>100,620</u>
Depreciated over	<u>3-5 years</u>

Financial statements 1 January - 31 December

Notes to the financial statements

DKK	<u>2019</u>	<u>2018</u>
5 Share capital		
Analysis of the share capital:		
71,500 A shares of DKK 1.00 nominal value each	71,500	71,500
39,793 B shares of DKK 1.00 nominal value each	39,793	39,793
67,036 C shares of DKK 1.00 nominal value each	67,036	0
18,408 D shares of DKK 1.00 nominal value each	18,408	29,500
	<u>196,737</u>	<u>140,793</u>

Analysis of changes in the share capital over the past 5 years:

DKK	<u>2019</u>	<u>2018</u>	<u>2017</u>	<u>2016</u>	<u>2015</u>
Opening balance	140,793	133,300	108,823	50,000	50,000
Capital increase	55,944	7,493	24,477	58,823	0
	<u>196,737</u>	<u>140,793</u>	<u>133,300</u>	<u>108,823</u>	<u>50,000</u>

6 Contractual obligations and contingencies, etc.

Other financial obligations

Other rent and lease liabilities:

DKK	<u>2019</u>	<u>2018</u>
Rent and lease liabilities	175,000	0

7 Contingent assets

The Company has tax loss carry-forwards totalling thousand DKK 8,634. The nominal value thereof is 22%, totalling thousand DKK 1,900, which has not been recognised in the balance sheet due to the uncertainty as to application of the tax losses.

**For
DrugStars ApS**

Titel
CEO

Firmarepræsentant
Claus Møldrup

E-mail
cm@drugstars.com

IP-adresse
212.112.152.79



Underskrevet digitalt
01/04/2020 13:57 [GMT+0200]

**For
DrugStars ApS**

Titel
Board chariman

Firmarepræsentant
Henrik Holmark

E-mail
holmarkhenrik@gmail.com

IP-adresse
212.27.16.103



Underskrevet digitalt
01/04/2020 14:13 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Anders Kjær

E-mail
ak@preseedventures.dk

IP-adresse
87.60.84.219



Underskrevet digitalt
01/04/2020 15:17 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Christian Hjortgaard

E-mail
ch@collektive.dk

IP-adresse
87.50.150.225



Underskrevet digitalt
03/04/2020 09:53 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Jesper Kilbæk

E-mail
jki@resourcecap.dk

IP-adresse
195.192.235.203



Undskrevet digitalt
05/04/2020 10:45 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Ulli Jendrik Koop

E-mail
ulli@dhventures.de

IP-adresse
2003:fb:5f07:3f00:c9cf:810f:5939:fa7e



Undskrevet digitalt
06/04/2020 11:55 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Eric Lagier

E-mail
eric@byfounders.vc

IP-adresse
94.145.14.247



Undskrevet digitalt
06/04/2020 14:10 [GMT+0200]

**For
DrugStars ApS**

Titel
Board member

Firmarepræsentant
Ekaterina Gianelli

E-mail
ekaterina@inventure.fi





























IP-adresse
2001:999:2:4228:70b8:5e10:eb87:c6fc















Undskrevet digitalt
08/04/2020 11:10 [GMT+0200]

DOKUMENT TITEL:

Financial Statements 2019

Hvad?	Hvem?	Hvornår
 Underskrevet & sendt	 ekaterina@inventure.fi	08/04/2020 11:10 [GMT+0200]
 Set	 ekaterina@inventure.fi	08/04/2020 11:10 [GMT+0200]
 Underskrevet & sendt	 eric@byfounders.vc	06/04/2020 14:10 [GMT+0200]
 Set	 eric@byfounders.vc	06/04/2020 14:10 [GMT+0200]
 Underskrevet & sendt	 ulli@dhventures.de	06/04/2020 11:55 [GMT+0200]
 Set	 ulli@dhventures.de	06/04/2020 11:46 [GMT+0200]
 Underskrevet & sendt	 jki@resourcecap.dk	05/04/2020 10:45 [GMT+0200]
 Set	 jki@resourcecap.dk	05/04/2020 10:40 [GMT+0200]
 Underskrevet & sendt	 ch@collektive.dk	03/04/2020 09:53 [GMT+0200]
 Set	 ch@collektive.dk	03/04/2020 09:49 [GMT+0200]
 Underskrevet & sendt	 ak@preseedventures.dk	01/04/2020 15:17 [GMT+0200]
 Set	 ak@preseedventures.dk	01/04/2020 15:17 [GMT+0200]
 Underskrevet & sendt	 holmarkhenrik@gmail.com	01/04/2020 14:13 [GMT+0200]
 Set	 holmarkhenrik@gmail.com	01/04/2020 14:06 [GMT+0200]

 Underskrevet & sendt	 cm@drugstars.com	01/04/2020 13:57 [GMT+0200]
 Set	 cm@drugstars.com	01/04/2020 13:57 [GMT+0200]
 Send til underskrift	 ko@drugstars.com	01/04/2020 13:42 [GMT+0200]
 Redigeret	 ko@drugstars.com	01/04/2020 13:41 [GMT+0200]
 Send til underskrift	 ko@drugstars.com	31/03/2020 21:57 [GMT+0200]
 Oprettet	 ko@drugstars.com	31/03/2020 21:56 [GMT+0200]

**For
DrugStars ApS**

Titel

Chairman of the meeting

Firmarepræsentant

Kim Laage Saltoft Olsen

E-mail

ko@drugstars.com

IP-adresse

212.242.97.62







Underskrevet digitalt

27/04/2020 11:46 [GMT+0200]



DOKUMENT TITEL:

Annual accounts 2019 - AGM approval

Hvad?	Hvem?	Hvornår
 Underskrevet & sendt	 ko@drugstars.com	27/04/2020 11:46 [GMT+0200]
 Oprettet	 ko@drugstars.com	27/04/2020 11:45 [GMT+0200]